Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TAC-003
- Development stage
- Preclinical
- Lead developer
- Tallac Therapeutics
- Modality
- MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Parenteral
01
Overview
**TAC-003** is a preclinical, tumor-targeted Toll-like receptor 9 agonist antibody conjugate developed by Tallac Therapeutics for Nectin-4-expressing solid tumors. It consists of a novel anti-Nectin-4 antibody conjugated to T-CpG, a CpG oligodeoxynucleotide TLR9 agonist. The antibody component is intended to concentrate the conjugate in Nectin-4-positive tumors, while T-CpG activates TLR9 within the tumor immune microenvironment to promote innate and adaptive antitumor immune responses, including immune-cell activation, inflammatory cytokine induction, phagocytosis, and durable antitumor activity in preclinical models. ([tallactherapeutics.com](https://www.tallactherapeutics.com/wp-content/uploads/2023/11/TAC-003_SITC-2023.pdf))
- Other names
- TAC 003TAC003TAC-003
02
Targets
PVRL4 (Nectin cell adhesion molecule 4)FcγR (Low affinity immunoglobulin gamma Fc region receptor II-c)TLR9 (Toll-like receptor 9)
Beyond the preview
Go deeper on TAC-003.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TAC-003.